Cargando…
Molecular Selection, Modification and Development of Therapeutic Oligonucleotide Aptamers
Monoclonal antibodies are the dominant agents used in inhibition of biological target molecules for disease therapeutics, but there are concerns of immunogenicity, production, cost and stability. Oligonucleotide aptamers have comparable affinity and specificity to targets with monoclonal antibodies...
Autores principales: | Yu, Yuanyuan, Liang, Chao, Lv, Quanxia, Li, Defang, Xu, Xuegong, Liu, Baoqin, Lu, Aiping, Zhang, Ge |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4813219/ https://www.ncbi.nlm.nih.gov/pubmed/26978355 http://dx.doi.org/10.3390/ijms17030358 |
Ejemplares similares
-
Potential Diagnostic and Therapeutic Applications of Oligonucleotide Aptamers in Breast Cancer
por: Wu, Xiaoqiu, et al.
Publicado: (2017) -
Chemical Modifications of Nucleic Acid Aptamers for Therapeutic Purposes
por: Ni, Shuaijian, et al.
Publicado: (2017) -
Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer
por: Lv, Quanxia, et al.
Publicado: (2016) -
The Application of Microfluidic Technologies in Aptamer Selection
por: Liu, Yang, et al.
Publicado: (2021) -
A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer
por: Li, Fangfei, et al.
Publicado: (2017)